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Study objective: Pediatric ovarian neoplasms with imaging appearance suggestive 
of teratoma are often presumed to have low risk of malignancy.  We assessed the 
pre-operative imaging appearance of pediatric malignant ovarian germ cell 
tumors (MOGCT) and the presence of associated teratoma in a series of MOGCT. 
Design: Retrospective review of clinical and pathology data. 
Setting: Multicenter trial for extra-cranial malignant germ cell tumors in children 
by the Children’s Oncology Group (COG study AGCT0132) that Included yolk sac 
tumor, embryonal carcinoma and choriocarcinoma. 
Participants: Girls age 0-18 years at enrollment with ovarian primary 
nonseminomatous malignant germ cell tumors. 
Interventions: Review of data forms including prospectively collected surgical 
checklist documenting imaging characteristics of the tumor and review of 
pathology reports. 
Main outcome measures: Description of imaging appearance and frequency of 
mixed histology with benign teratoma elements.   
Results: 138 girls (11 months to 20 years) had primary ovarian tumors.  Imaging 
appearance and pathology information were available for 133 patients. Among 
the 133 patients, tumor appearance was solid (10.5 %), solid with calcification 
(3.0%), mixed cystic and solid (58.7 %), mixed cystic and solid with calcification 
(24.8 %) and unknown (3.0 %).  54% had elements of teratoma in addition to 
malignant histology. 
Conclusions:  Mixed cystic and solid appearance with or without calcification was 
seen in 83.5% of pediatric ovarian malignant germ cell tumors.  Associated benign 
teratoma was common.  The presence of a mixed cystic and solid appearance on 
pre-operative imaging should not dissuade the surgeon from obtaining 



















Ovarian masses are encountered at all ages in childhood and adolescence.  In neonates, these masses 
are almost exclusively follicular cysts due to maternal hormone influence and most can be managed 
non-operatively [1].  Simple cysts beyond the neonatal period may present with pain due to hemorrhage 
or torsion but are clearly recognized by their simple wall, unilocular appearance and absence of any 
solid components.   True neoplastic lesions account for approximately 73% of masses and 16-22% of 
these are malignant [2,3].   Since the majority of neoplastic lesions are benign teratomas (also called 
dermoid cysts) which have a mixed cystic and solid appearance and frequently have calcifications, 
surgeons may assume that this finding on imaging indicates a benign tumor.  This leads to incomplete 
staging if a malignant tumor is present and may impact the subsequent need for chemotherapy. 
   Recent attention has been focused on imaging characteristics that are predictive of malignancy, but 
non-neoplastic simple cysts are often included in these series and will have an impact on the risk 
predictor calculations.    Diameter greater than 9 cm and solid appearance have been predictive of 
malignancy in recent pediatric series of ovarian masses but they have included simple cysts in the 
calculations.  In addition, these reports are based on case series of ovarian masses from single 
institutions so the actual number of malignant cases is very small and the size cutoff is not absolute [2,4, 
5].  Once simple cysts are excluded, the important dilemma is whether or not a neoplastic lesion may be 
malignant.   The size range and imaging appearance of pediatric malignant ovarian germ cell tumors is 
unknown.   This review was undertaken to summarize the preoperative ovarian imaging findings in the 
Children’s Oncology Group study AGCT0132 of all the enrolled ovarian malignant germ cell tumors in 
children. 
PATIENTS AND METHODS 
The Children’s Oncology Group study AGCT0132 for malignant extra cranial germ cell tumors enrolled 
patients between November 2003 and July 2011.  Details have been reported elsewhere [ 6,7,8].  Data 
for this analysis is current to June 30, 2018.  Required histology included yolk sac, embryonal carcinoma 
or choriocarcinoma.  Pure germinoma and pure immature teratoma were not eligible. Low risk (stage I 
gonadal) patients were treated with surgery and surveillance with chemotherapy reserved for relapse.   
Intermediate risk (stage I-III extragonadal, stage II-IV testicular, stage II-III ovarian) patients were treated 
with chemotherapy in addition to surgery.      
 Primary ovarian malignant germ cell tumors were seen in 138 girls:  29 low risk (stage I), and 109 
intermediate risk (stage II and III).   A surgical checklist was required at enrollment for all patients.   The 
ovarian surgical checklist included a request for the institution to provide an imaging description of the 
tumor as one of the following: purely cystic, cystic with calcifications, purely solid, solid with 
calcifications, mixture of solid and cystic components, mixture of solid and cystic components with 
calcifications, or unknown.   Unknown appearance category was needed for those without preoperative 
imaging or with procedure done at an outside institution without submission of preoperative imaging.  
The surgical checklists and institutional and central review pathology reports were reviewed to evaluate 
imaging characteristics and histology for girls with ovarian germ cell tumors.  
RESULTS 
Completed surgical checklists, operative notes and pathology reports were available for 133 of 138 
patients with characteristics as seen in Table 1 and form the basis for this review.   Four intermediate 
risk patients and one low risk patient did not have a surgical checklist submitted and could not be 
included.   As the study design excluded pure germinoma and there were no pure embryonal 
carcinomas, all patients had elevated tumor markers at diagnosis.  Alpha-fetoprotein (AFP) was measured 
in all patients (median: 3394.5 ng/ml, range:  2 – 4233000 ng/ml) and beta human choriono-
gonadotrophin (BHCG) (median: 2 mIU/mL, range: 0 – 999140 mIU/mL).    The imaging appearance 
according to the surgical checklists is described in Table 2.   No patients had purely cystic tumors with or 
without calcification.  Overall, 58.7%% of girls had an imaging appearance that was a mixture of solid 
and cystic components and 24.8% had a mixture of solid and cystic components with calcification.  
Seventy-two (54%) had mixed histology that included teratoma (mature or immature) along with 
malignant histology (Table 3).  Maximal tumor dimension ranged from 5.5 to 33.5 cm with a median of 
16 cm.   
   
DISCUSSION 
 This study was undertaken to evaluate the imaging characteristics of malignant nongerminoma ovarian 
germ cell tumors in pediatric and adolescent patients to determine if there were distinguishing features 
which could aid in preoperative discussion and planning of the operation.   We found that over 80% had 
a mixed cystic and solid appearance which could easily be seen in a mature teratoma.   We also noted 
that associated elements of benign teratoma were common and were seen in more than half of 
patients.  
 Ovarian masses in the pediatric age group are somewhat uncommon and have an overall risk of 
malignancy of 10-15%.  A recent paper [5] reviewed the imaging and marker characteristics of ovarian 
masses from two free standing pediatric institutions.  They included all ovarian masses in patients less 
than 18 years of age undergoing surgical management of ovarian masses.  That series included 185 
patients with malignancy found in 11%.  Imaging findings in their series revealed simple cysts in 24 
(12.9%), solid masses in 34 (18.3%) and heterogeneous masses in 127 (68.6%).  They did not distinguish 
whether calcification was present.  All of the simple cysts were benign.  Our series of exclusively 
malignant germ cell tumors also found no simple cysts on imaging.   If the simple cystic lesions are 
excluded from the above series; the distribution of solid and heterogeneous appearance was 34/158 
(21.5%) solid tumors and 127/158 (80.3%) heterogeneous masses.  This distribution of imaging 
appearance is similar to our series of patients with malignant germ cell tumors in whom we noted 13.5% 
solid and 84.9% heterogeneous (mixed) masses.  In addition, although risk factors for malignancy 
included size greater than 9 cm in greatest dimension, the malignant tumors in this series ranged in size 
from 5.5 to 33.5 cm.  These results indicate that imaging characteristics and size alone do not 
differentiate benign from malignant ovarian masses.   It was disappointing to note on review of the 
operative notes in this series that there were several instances where the surgeon commented that the 
mass appeared to be classic for teratoma and/or failed to do full tumor staging.  Mention of 
preoperative tumor markers was seldom included in the operative notes.  It should also be noted that 
not all malignant germ cell tumors will have elevated serum markers.   In all instances ovarian masses 
that are not simple cysts should be approached with caution and pre-operative investigation including 
tumor markers must be completed.  Full pediatric surgical staging should always be undertaken for 
ovarian masses regardless of tumor marker findings. 
Ovarian masses in the pediatric and adolescent age group are managed by a variety of surgical 
specialists.  These factors make the experience for any individual surgeon limited both by experience 
and by training and contribute to the failure to undertake complete surgical staging at the primary 
procedure.  The finding of cystic areas or calcifications on preoperative imaging may lead to the 
assumption that the mass is a benign teratoma and a limited procedure is done.  Malignancy is not 
discovered until the pathology has been assessed and the opportunity for appropriate staging has been 
lost.  The increasing and appropriate emphasis on ovarian sparing procedures to protect fertility in this 
age group has led to attempts to risk stratify for malignancy based on preoperative assessment.  Recent 
reviews of single institution series of ovarian masses in children have evaluated preoperative tumor 
marker and imaging findings to aid in risk stratification of malignancy.   As none of these classifications 
are 100% sensitive or specific, there is a possibility of under-staging by omitting required steps, or of up-
staging by deliberately violating the tumor capsule of a malignant ovarian tumor during the surgical 
procedure.    As an example, failure to collect peritoneal fluid or do a complete assessment of the 
peritoneal cavity may lead to missed pathology.   In the previous Pediatric Oncology Group/Children’s 
Cancer Study Group (POG/CCSG) intergroup study that formed the basis for the revised COG guidelines, 
5 girls with otherwise stage I tumors were accurately recognized to be stage III based on peritoneal 
cytology alone confirming the importance of complete assessment [9].  Furthermore, surgical technique 
aimed at reducing mass size by planned puncture, or by an accidental capsule entry or rupture during 
manipulation for a presumed benign lesion; will upstage a patient who might otherwise be a candidate 
for surgery and surveillance. Laparoscopic enucleation of ovarian masses has been shown to result in a 
higher rupture rate of the lesion than open technique [10].    
  The current pediatric surgical ovarian germ cell tumor guidelines used by the Childrens Oncology Group 
(COG) were published in 2004 [9].  Despite their simplicity, compliance with the guidelines remains a 
significant problem.  A 15-year retrospective study by Oltmann et al in 2010 [4] revealed only 24% 
compliance with COG guidelines; and a similar 22-year retrospective study by Madenci et al in 2016 [11] 
showed 27% compliance with guidelines, without any change in performance after the 2004 guidelines 
were published.  The pediatric guidelines are less extensive than the adult FIGO guidelines in terms of 
tissue sampling, but remain critical in accurate assessment and treatment planning.   Inspection and 
documentation of all defined parameters in the operative note are absolute requirements for 
confirmation of stage I status and the possibility that a surveillance strategy, rather than chemotherapy, 
can be recommended.   “Not documented” has to be considered as not having been done.   In the 
surgery and surveillance arm of the AGCT0132 study for  stage I ovarian tumors, relapse occurred in 9 of 
21 girls who were confirmed as stage I by central review; but relapse was seen in 3 of 4 girls who were 
assigned as stage I by the enrolling institution but had incomplete staging on central review [6].   Overall 
survival for the stage I tumors was 96% at 4 years. 
Limitations of this study include the inclusion of only malignant nongerminoma ovarian tumors.  A 
strength of this study is the large number of malignant tumors with prospectively documented imaging 
appearance that could not be obtained in a single institution review.  
 It is recommended that all pediatric and adolescent ovarian neoplasms be approached with the concern 
that malignant histology may be present, regardless of tumor size or appearance, and that the COG 
guidelines for staging be completed.  The guidelines include collection of peritoneal fluid for cytology, 
inspection and documentation of omentum, peritoneal surfaces, lymph nodes and opposite ovary.  
Biopsy of any abnormal findings is required.  The tumor should be removed without violation of the 
tumor capsule in the peritoneal cavity.  These tasks are easily accomplished in all patients with minimal 
expenditure of time and little to no morbidity.    Preoperative CT imaging provides guidance to aid in 
identifying suspicious, enlarged nodes that should be biopsied.  A low yield of positive peritoneal 
cytology should be expected [12], but the information is of high importance.    A laparoscopic approach 
does not preclude the steps of the staging procedure, and inspection of the peritoneal surfaces may 
even be more easily accomplished.   The ovarian mass should be excised with care to avoid rupture of 
the tumor capsule.  Tumors with elevated markers should be treated with oophorectomy.  Tumors with 
negative markers may be considered for an ovary sparing approach but complete performance and 
documentation of the staging procedure is imperative and should always be done.  Care should be taken 
to minimize the risk of tumor spill when excising the mass from the ovarian parenchyma as this not only 
upstages malignant tumors but also increases the risk of recurrence for benign teratomas [10].  
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